Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Free Cash Flow: 2013-2024

Historic Free Cash Flow for Zevra Therapeutics (ZVRA) over the last 12 years, with Dec 2024 value amounting to -$69.7 million.

  • Zevra Therapeutics' Free Cash Flow rose 122.90% to $4.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$24.2 million, marking a year-over-year increase of 65.21%. This contributed to the annual value of -$69.7 million for FY2024, which is 105.92% down from last year.
  • As of FY2024, Zevra Therapeutics' Free Cash Flow stood at -$69.7 million, which was down 105.92% from -$33.8 million recorded in FY2023.
  • In the past 5 years, Zevra Therapeutics' Free Cash Flow registered a high of $10.3 million during FY2021, and its lowest value of -$69.7 million during FY2024.
  • In the last 3 years, Zevra Therapeutics' Free Cash Flow had a median value of -$33.8 million in 2023 and averaged -$40.8 million.
  • In the last 5 years, Zevra Therapeutics' Free Cash Flow skyrocketed by 624.19% in 2021 and then tumbled by 281.97% in 2022.
  • Zevra Therapeutics' Free Cash Flow (Yearly) stood at -$2.0 million in 2020, then spiked by 624.19% to $10.3 million in 2021, then tumbled by 281.97% to -$18.8 million in 2022, then tumbled by 79.86% to -$33.8 million in 2023, then slumped by 105.92% to -$69.7 million in 2024.